Answers are grounded in this paper and cite their sources.
Drug candidates supported by genetic evidence are more likely to succeed in clinical trials, with genome-wide association studies (GWAS) providing a key source of such evidence. Standard GWAS approaches assume additive effects of alleles on the phenotype, but non-additive models have also successfully identified novel associations across various traits. Despite their potential, the large-scale application of non-additive GWAS across thousands of phenotypes in biobanks has been limited by high computational costs. To address this challenge, we present a method that leverages the correlation between additive and non-additive p-values to prioritize variants likely to reach genome-wide significance in non-additive analyses. Applied to the FinnGen dataset comprising 500,349 individuals and 2329 phenotypes, this method reduces computational costs by three orders of magnitude while retaining nearly all true non-additive associations, identifying 781 novel loci missed by additive GWAS. We report fine-mapping and colocalization with 571 datasets for novel loci, uncovering likely causal variants and potential insights into biological mechanisms. The authors introduce a cost-efficient, non-additive genome-wide association study pipeline that, when applied to a dominant analysis of 2329 phenotypes in 500,349 individuals, reduced computational costs from $27,000 to $39 and identified 781 new associations.
No takes yet. Share an insight, caveat, or question.
Molotkov et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: